Curo Group

Curo is a biotechnology company focused on developing next-generation senolytic therapies to treat age-related diseases and improve healthspan. The company's primary technology centers on disrupting the interaction between the FOXO4 transcription factor and the p53 tumor suppressor protein, which selectively induces apoptosis in senescent cells while sparing healthy ones. By targeting these "zombie cells," Curo aims to address the root causes of various chronic conditions, including fibrosis and metabolic dysfunction. Founded by leading experts in senescence biology, the company is advancing a pipeline of peptide-based and small molecule candidates through pre-clinical development. Curo's approach represents a significant shift toward regenerative medicine and longevity-focused therapeutics.